鶹ýӰ

Meeting Coverage

AACR

American Association for Cancer Research

Possible New Standard for Treated Advanced CRC With KRAS Mutations

Adagrasib plus cetuximab leads to responses in one-third of patients, median OS of 15.9 months

AACR over a photo of San Diego Convention Center in San Diego, CA

Latest AACR Meeting Coverage

Neoadjuvant Chemo-IO Promising in Borderline Resectable Pancreatic Cancer

Combination associated with favorable R0 resection and survival rates

April 10, 2024
Bispecific Checkpoint Inhibitor Improves Survival in Advanced Gastric/GEJ Cancer

Almost 50% improvement in median survival, but against a suboptimal control regimen

April 10, 2024
Immunotherapy After Definitive Therapy Flops in Head and Neck Cancer

No event-free survival benefit with atezolizumab versus placebo in phase III trial

April 10, 2024
Accelerated Aging Linked to Recent Increase in Early-Onset Solid Tumors

Strength of association increased in more recent birth cohorts

April 9, 2024
Novel PARP1 Inhibitor Shows Promise in Breast Cancer

The drug had favorable safety compared with first-generation PARP inhibitors in phase I/II study

April 9, 2024
High Response Rate in R/R Multiple Myeloma With Bispecific Antibody

ORR of 71% that deepened over time and favorable safety profile with linvoseltamab

April 8, 2024
Can Late-Stage Cancer Incidence Serve as an Endpoint for Screening Trials?

Study shows it may be an alternative to cancer-specific mortality for some cancers, but not all

April 8, 2024
Most Cancer Drugs Granted Accelerated Approval Fail Confirmatory Trials

Only 43% showed clinical benefit within 5 years

April 8, 2024
Awareness of HPV's Link to Cancer Lags as Cases Continue to Increase

Clear decline for cervical cancer, awareness of other cancers remains stagnant

April 21, 2023
Genomics Add Insight Into Worse Colorectal Cancer Outcomes in Black Patients

Fewer actionable mutations, less likely to meet genomic criteria for immunotherapy

April 19, 2023
CAR T-Cell Therapy Shows Promise in Advanced Kidney Cancer

ORR of 30% in patients with CD70-positive disease using off-the-shelf, allogeneic product

April 19, 2023
Many With Cancer Predisposition Diseases Unaware of Genetic Status

Moreover, a significant proportion do not qualify for genetic screening under current guidelines

April 19, 2023
Robust PSA Drops With Radionuclide Therapy in Castration-Resistant Prostate Cancer

All but one patient had a PSA decline after a fractionated dose of 225Ac-J591

April 18, 2023
Novel Antibody Induces Durable Responses in Heavily Pretreated Myeloma

Overall response rate of 90% in patients who received highest doses of REGN5459

April 18, 2023